CSA-131
Prevention/Treatment of infections (Candida auris, Aspergillus, Pseudomonas, Klebsiella pneumoniae) in Cystic Fibrosis
Pre-clinicalActive
Key Facts
Indication
Prevention/Treatment of infections (Candida auris, Aspergillus, Pseudomonas, Klebsiella pneumoniae) in Cystic Fibrosis
Phase
Pre-clinical
Status
Active
Company
About Kinnear Pharmaceuticals
Kinnear Pharmaceuticals is a private, preclinical-stage biotech company based in San Diego, founded in 2019. The company is developing a versatile immunomodulatory drug platform based on synthetic Ceragenins, small molecules designed to mimic and enhance the body's innate immune defenses against pathogens. Its lead candidate, CSA-131, has received FDA Qualified Infectious Disease Product (QIDP) designation for preventing/treating infections in cystic fibrosis patients. Kinnear's strategy targets difficult-to-treat infections, aiming to overcome antimicrobial resistance with a novel mechanism of action.
View full company profile